Pharmaceuticals

Regencell Bioscience

Regencell Bioscience released FY2026 Q2 earnings on May 8 (EST), actual revenue USD 0, actual EPS USD -0.0053

Regencell Bioscience released FY2026 Q1 earnings on May 8 (EST) with actual revenue of USD 0 and EPS of USD -0.0053

Regencell Bioscience released FY2025 9 Months earnings on October 31 (EST), actual revenue USD 0, actual EPS USD -0.0054

Regencell Bioscience released FY2025 Q3 earnings on October 31 (EST), actual revenue USD 0, actual EPS USD -0.0017

Regencell Bioscience released FY2025 annual earnings on October 31, 2025, EST: Actual Revenue USD 0, Actual EPS USD -0.0072

Regencell Bioscience released FY2025 Q4 earnings on October 31 (EST) with actual revenue of USD 0 and EPS of USD -0.0017

Brain 再生科技 US stocks night session price down 3.27%

Brain Regeneration Technology Soars Over 25% in Pre-Market

Brain Regeneration Technology's stock price up nearly 180 times year-to-date

Regencell Bioscience released FY2025 Semi-Annual Earnings on June 30 (EST), actual revenue USD 0, actual EPS USD -0.0037

Regencell Bioscience released FY2025 Q2 earnings on June 30 (EST), actual revenue USD 0, actual EPS USD -0.0018

Regencell Bioscience released FY2025 Q1 earnings on June 30 (EST) with actual revenue of USD 0 and EPS of USD -0.0018

Brain Regeneration Technology Holdings Appoints New Independent Director

Brain Regeneration Technology Holdings Announces 2025 First Half Year Financial Report

Brain Regeneration Tech Pre-Market Drop Over 13% in US Stocks

Brain Regeneration Tech Announces 38:1 Stock Split, Shares Soar

US Senate Passes GENIUS Act to Promote Stablecoin Development

Brain Regeneration Technology's US Stocks Soar Pre-Market

Brain Regeneration Tech Begins Trading Post-Stock Split Adjustment

US Stock Market Opens Positively, Dow Jones Up Over 400 Points

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

LABU

ARKG

SBIO

Glancy Prongay Wolke & Rotter LLP announces that investors who lost money in Regencell Bioscience Holdings Limited (NASDAQ: RGC) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that from October 28, 2024, to October 31, 2025, the company failed to disclose vulnerabilities to market manipulation, exposing investors to significant financial risks. Interested parties must act before June 23, 2026, to participate.

prnewswire

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

VG Health

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

iShares US Pharma

ALPS Medical Breakthrough

16:10 ETRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Faruqi & Faruqi, LLP is investigating potential claims against Regencell Bioscience Holdings Limited and reminds investors of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action. The firm alleges that Regencell made false statements and failed to disclose vulnerabilities, leading to significant financial risks for investors. Following a DOJ investigation announcement, Regencell's share price fell 18.56%. Investors who suffered losses are encouraged to contact the firm for legal options.

08:12 ETRGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026

Pomerantz LLP has filed a class action lawsuit against Regencell Bioscience Holdings Limited and certain officers, alleging violations of federal securities laws. The lawsuit covers investors who acquired Regencell securities between October 28, 2024, and October 31, 2025. The complaint highlights significant fluctuations in Regencell's stock price, which rose dramatically despite the company having no approved products or revenue. Investors have until June 23, 2026, to seek lead plaintiff status.

21:53 ETPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited   and Certain Officers - RGC

Regencell Bioscience Holdings Limited (NASDAQ: RGC) shareholders who incurred losses may lead a securities fraud class action lawsuit. The Law Offices of Frank R. Cruz announced that investors can participate before the June 23, 2026 deadline. The lawsuit alleges that from October 28, 2024, to October 31, 2025, the company failed to disclose vulnerabilities to market manipulation, exposing investors to significant risks and misleading them about the company's operations and prospects. Interested investors can contact the law firm for more information.

15:03 ETRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Rosen Law Firm is reminding investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC) about a securities fraud lawsuit. Investors who purchased securities between October 28, 2024, and October 31, 2025, may be eligible for compensation without upfront costs. A lead plaintiff must be appointed by June 23, 2026. The lawsuit alleges that Regencell made misleading statements, exposing investors to financial risks. Interested parties can contact the firm for more information on joining the class action.

15:37 ETRGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

Regencell Bioscience Holdings Limited (RGC) shareholders who incurred losses are urged to contact the Law Offices of Howard G. Smith before the June 23, 2026 deadline to file a lead plaintiff motion in a securities fraud lawsuit. The lawsuit stems from Regencell's disclosure of a DOJ investigation into its trading practices, which led to a significant drop in stock price. Investors who purchased shares between October 28, 2024, and October 31, 2025, may be eligible to participate in the class action.

MorningStar

Deadline Approaching: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Rosen Law Firm is reminding investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC) about a class action lawsuit related to securities fraud. Investors who purchased shares between October 28, 2024, and October 31, 2025, may be eligible for compensation. The deadline to apply as lead plaintiff is June 23, 2026. The lawsuit alleges that Regencell made misleading statements that exposed investors to financial risks. Interested parties can contact the firm for more information on joining the class action.

19:10 ETRGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

Regencell Bioscience(RGC.US)